title: SCV-07 (SciClone Pharmaceuticals/Verta).
abstract: SciClone Pharmaceuticals and Verta are developing SCV-07, the lead in a series of immnunostimulants from Verta, for the potential treatment of tuberculosis and hepatitis C virus infection. Phase II clinical trials of the compound are ongoing.
authors.affiliation: Scripps Clinic, Division of Gastroenterology/Hepatology, La Jolla, CA 92037, USA. Aspinall.Richard@scrippshealth.org
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Aspinall
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Pockros
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004151:Dipeptides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004353:Drug Evaluation, Preclinical; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D007273:Injections, Intramuscular; D007836:Lassa virus / Q000187:drug effects; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000254:growth & development; D027383:Papillomaviridae / Q000187:drug effects; D013154:Spleen / Q000166:cytology / Q000187:drug effects; D013950:Thymus Gland / Q000166:cytology / Q000187:drug effects; D014376:Tuberculosis / Q000188:drug therapy*
chemical_list: D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D000998:Antiviral Agents; D004151:Dipeptides; C470075:golotimod